Trial Profile
Safety and Immunogenicity of Human Papillomavirus (HPV) Vaccine [human papillomavirus vaccine recombinant quadrivalent] in Solid Organ Transplant Recipients.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Jul 2015
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Cervical cancer; Cervical intraepithelial neoplasia; Genital warts; Human papillomavirus infections
- Focus Pharmacodynamics
- 17 Aug 2012 Planned end date changed from 1 Mar 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.
- 06 Sep 2011 Planned End Date changed from 1 Dec 2010 to 1 Mar 2012 as reported by ClinicalTrials.gov.
- 30 Aug 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.